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Abstract
Background: In 2007, various countries around the world notified 178677 cases of cholera and
4033 cholera deaths to the World Health Organization (WHO). About 62% of those cases and
56.7% of deaths were reported from the WHO African Region alone. To date, no study has been
undertaken in the Region to estimate the economic burden of cholera for use in advocacy for its
prevention and control. The objective of this study was to estimate the direct and indirect cost of
cholera in the WHO African Region.
Methods: Drawing information from various secondary sources, this study used standard cost-of-
illness methods to estimate: (a) the direct costs, i.e. those borne by the health-care system and the
family in directly addressing cholera; and (b) the indirect costs, i.e. loss of productivity caused by
cholera, which is borne by the individual, the family or the employer. The study was based on the
number of cholera cases and deaths notified to the World Health Organization by countries of the
WHO African Region.
Results: The 125018 cases of cholera notified to WHO by countries of the African Region in 2005
resulted in a real total economic loss of US$39 million, US$ 53.2 million and US$64.2 million,
assuming a regional life expectancies of 40, 53 and 73 years respectively. The 203,564 cases of
cholera notified in 2006 led to a total economic loss US$91.9 million, US$128.1 million and US$156
million, assuming life expectancies of 40, 53 and 73 years respectively. The 110,837 cases of cholera
notified in 2007 resulted in an economic loss of US$43.3 million, US$60 million and US$72.7
million, assuming life expectancies of 40, 53 and 73 years respectively.
Conclusion:  There is an urgent need for further research to determine the national-level
economic burden of cholera, disaggregated by different productive and social sectors and
occupations of patients and relatives, and national-level costs and effectiveness of alternative ways
of scaling up population coverage of potable water and clean sanitation facilities.
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Background
In 2002, the world lost a total of 1 490 126 000 disability-
adjusted life years (DALYs) from various diseases and con-
ditions [1]. About 61 966 000 of the lost DALYs resulted
from diarrhoeal diseases. An estimated 37.5% of the diar-
rhoea-related DALYs was lost in the World Health Organ-
ization (WHO) African Region alone.
Cholera is one of the main causes of diarrhoea. In 1997, a
total of 118 349 cholera cases and 5 853 deaths were
reported to WHO by countries of the African Region [2].
By the end of 2005, the number of cholera cases notified
from the Region had increased to 125 018 (94.8% of the
total 131 943 cholera cases reported globally). However,
the number of cholera-related deaths reported from the
Region had decreased to 2230 (98.2% of the 2272 cholera
deaths reported globally) [3]. According to WHO [3],
"Globally, the actual number of cholera cases is known to
be much higher; the discrepancy is the result of underre-
porting and other limitations of surveillance systems,
such as inconsistency in case definition and lack of a
standard vocabulary (p.297)". The underreporting could
be due to fear, among the notifying countries, of the
potential negative impact on their tourism industry and
export of commodities.
The etiological agent that causes cholera is Vibrio cholerae.
The bacterial agent is associated with conditions that force
populations to live under conditions of overcrowding,
inadequate housing, inadequate excreta disposal systems,
lack of potable water, floods, unhygienic human behav-
ioural practices, poverty, civil unrest leading to internal
displacement of people, and unhygienic food production,
distribution and handling systems [4,5]. In sub-Saharan
Africa, 63% of the population has no sustainable access to
improved sanitation and 44% has no sustainable access to
improved water sources [6]. The ever-increasing propor-
tion of vulnerable African populations who live in the
above-mentioned unsanitary conditions is constantly at
risk of cholera outbreaks [2].
Prevention of cholera outbreaks entails mitigating the
above-mentioned factors, especially assuring sustainable
access to improved sanitation and water sources and
observance of hygienic human behavioural practices.
Cholera treatment entails rehydration with replacement
of electrolytes lost. According to WHO guidelines [7],
patients with: no dehydration should receive oral rehydra-
tion salts (ORS) at home; mild dehydration (who are rest-
less and irritable, have sunken eyes, dry mouth, thirsty –
drinks eagerly, skin pinch goes back slowly) should
receive ORS and very close surveillance; severe dehydra-
tion (manifesting various symptoms – lethargic, uncon-
scious, floppy, very sunken eyes, unable to drink, mouth
very dry, skin pinch goes back very slowly, lack of tears
among children) should receive intravenous therapy,
antibiotics and ORS.
To the best of our knowledge, prior to the study reported
in this paper, no other study has attempted to estimate the
economic burden of cholera in the WHO African Region.
This paper attempts to answer the question: from the
patient's (family) and ministries of health perspective,
what is the total cost of cholera in the African Region. The
specific objectives were to estimate: (a) the direct costs, i.e.
those borne by the health-care services and the families in
directly addressing the cholera problem; and (b) the indi-
rect costs, i.e. mainly the losses in productivity caused by
the disease, borne by the individual, the family or the
employer.
Methods
Data
The data on the number of cases notified to WHO in
2005, 2006 and 2007 were obtained from a WHO Data-
base [8]. The unit costs of the "hotel" component (person-
nel, capital, utilities, maintenance, etc.) of hospitals and
health centres were obtained from a WHO website [9].
Adam, Evans and Murray [10] provided the details of how
the country-specific hospital and health centre "hotel"
cost component was estimated. The standard treatment
for mild/moderate and severe cholera was obtained from
WHO guidelines [11]. Prices for medicines were obtained
from the WHO/AFRO essential medicines price indicator
document [12]. The average cost of a diagnostic test for
cholera was collected purposively from private laboratory
services in 10 Member States. The costs borne by house-
holds were obtained from the World Health Survey [13]
and adjusted for inflation using information from the
International Monetary Fund (IMF) Database [14]. The
information on gross national income per capita was
obtained from the World Bank database [15]. All the costs
estimates for 2005, 2006 and 2007 were eventually
expressed in 2002 prices using the average consumer price
indices for the three years [14].
Conceptual framework
Figure 1 presents an analytical framework of the cost of
cholera in the WHO African Region. The framework con-
sists of six components. The first component consists of
the "hotel" hospital and health centre costs. It excludes
cholera drugs and diagnostic tests. It includes the cost of
administration, health personnel remunerations, in-serv-
ice training, per diem and transport for personnel, materi-
als, utilities (i.e. electricity, water, telephone, and
postage), maintenance (of vehicles, equipment and build-
ings), and capital costs (i.e. vehicles, equipment and
buildings) [9].BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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The second component consists of the cost of laboratory
diagnosis of cholera cases. We assumed that the prices
charged by private hospital laboratories for cholera diag-
nosis approximate the opportunity cost of resources used
to perform laboratory test. This data was purposively col-
lected by WHO Country Office health systems advisors in
10 countries, i.e. Burkina Faso, Congo, Ghana, Kenya,
Malawi, Mauritania, Mauritius, Namibia, Senegal and
Zambia.
The third component consists of the cost of medicines
used to treat cholera cases. The estimations for medicines
are based on the 125018 cases notified to WHO in 2005;
203564 cases notified in 2006; and 110837 cases notified
in 2007 [8]. The standard treatment regimen for mild/
moderate dehydration patients are ORS and very close
surveillance [10]. According to a personal communication
with the WHO Regional Adviser for cholera control pro-
gramme, mild cholera cases will require on average about
three litres of ORS solution over a period of about three
Cost of cholera in WHO African region Figure 1
Cost of cholera in WHO African region.
"Hotel" Component
- Administration
- Health personnel 
remunerations
- Inservice training
- Per diem for personnel
- Transport for personnel
- Materials
- Utilities (i.e., electricity, 
water, telephone, and 
postage)
- Maintenance (of vehicles, 
equipment, and buildings)
- Capital costs (i.e., 
vehicles, equipment, and 
buildings)
Diagnosis
- Inputs used in laboratory 
test for vibrio cholerae
Cost of Cholera in WHO African Region
Medicines
Mild/moderate state:
- Oral rehydration salts 
(ORS)
Severe state:
-Doxycline
-Erythromycin
- Ringer Lactate
Cots borne by  patients 
&
family members
- Consultation fees
- Medicines
- Tests
- Transport
Productivity losses
-Time of hospitalized 
cases in severe state
- Reduction in function 
performance for mild/
moderate cases
-Time of family carers
- Time lost due to 
premature death
Other losses
- Loss in tourism 
incomes
- Loss in revenues 
from export of goods 
(due to international 
ban)
Table 1: Standard treatment regimens for severe cholera cases
Antibiotics Dose Children Adults 
(=>15 years)
Pregnant 
women
Under 1 year 1–4 years 5–14 years
Erythromycin
250 mg
30 mg/kg divided 4 
times per day for 3 
days
1/4 tablet
4 times/day
3 days
1/2 tablet
4 times/day
3 days
1 tablet
4 times/day
3 days
2 tablets
4 times/day
3 days
2 tablets
4 times/day
3 days
Doxycline 300 mg
Single dose
3 tablets
Ringer Lactate 
solution (IV) in 
litres
1 litre per day for 
3 days
1 litre per day for 
3 days
1 litre per day for 
3 days
1 litre per day for 
3 days
1 litre per day for 
3 days
1 litre per day for 
3 days
Source: WHO [11].BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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days. The standard treatment regimens for severely dehy-
drated patients are summarized in Table 1.
The fourth component consists of costs borne by patients
and family members. The average cost borne by patient
and family members was obtained from the World Health
Survey [13] and adjusted for inflation rates in 2005, 2006
and 2007 [14] to obtain the costs for those years.
The fifth component is made up of productivity losses.
These include: severe case's hospitalization time; reduc-
tion in function performance for mild/moderate cases; the
time family carers spend accompanying cases to a health
facility and visiting those that are hospitalized; and pro-
ductive time lost due to premature death. Culturally, the
majority of the people in African countries never retire. In
the absence of social security systems covering entire pop-
ulations, survival of the self-employed people largely
depends on their ability to undertake their activities of
daily living until they die. Even the few who are employed
in the formal sector, after attaining official retirement age,
they continue to lead economically active lives (in trade,
farming, animal husbandry, etc.) for their remaining life
expectancies. We did cost estimations for three scenarios,
assuming people would work until they attain the age of
(i) 73 years, i.e. the maximum life expectancy in the Afri-
can Region (in Mauritius); (ii) 53 years, i.e. the average
life expectancy in the Region; and (iii) 40 years, i.e. the
minimum life expectancy in the Region (in Sierra Leone)
[16]. Even for children (0–14 years) who die prematurely,
we valued the years lost above 15 at the current gross
national income per year, since they constitute a perma-
nent loss from the future labour force. The productive
years of life lost were discounted at a rate of 3% [17].
The last component consists of other losses to the affected
African country's economies. Cholera outbreaks impact
negatively on both domestic and international demand
for tourism industry services of affected countries. There is
evidence that when there are cholera outbreaks in African
countries, developed countries usually discourage their
citizens from traveling to those countries, which may
reduce the numbers of tourists to affected countries. Con-
sequently, that could lead to losses of revenues for the
tourism industry, unemployment of people whose liveli-
hood is dependent directly or indirectly on tourism, and
reduction in tax revenues for the governments. In addi-
tion, it is not unusual to have international ban slapped
on export of commodities from countries experiencing
cholera outbreaks. When the latter happens, it may
adversely affect the foreign exchange flows into the
affected countries, which is likely to have many other
externality costs.
The current study focuses on cost of "hotel" component,
diagnosis, medicines, cost borne by patients and accom-
panying family members, and productivity losses. It was
not possible to obtain the data needed to estimate the
losses in tourism incomes and export revenues.
Cost Estimation
The total cost (TC) incurred by ministries of health, chol-
era patients and family members equals direct cost plus
indirect cost (which is value of productivity time lost) plus
intangible cost (including physical and psychological
pain) [18,19].
Direct cost
The total direct cost (DC) is the sum of total costs borne
by government in operating and organizing health facility
services and the out-of-pocket expenses borne by patients,
family members and relatives. The cost of operating and
organizing health facility services is the sum of the costs of
medicines; cost of personnel time, utilities, non-pharma-
ceutical supplies, materials, maintenance of capital
inputs, acquisition of capital inputs (vehicles, equipment
and buildings); and cholera tests.
Cost of medicines
Medicines cost is the sum of the costs of medicines for
treating all children with mild/moderate cholera at health
centre; adults (>= 15 years) with mild/moderate cholera at
health centre; all under-1-year-old children with severe
cholera at a hospital; all children aged between 1 and 4
years with severe cholera at a hospital; all children aged
between 5 and 14 years with severe cholera at a hospital;
and all adults (i.e. 15 years and above) with severe cholera
at a hospital.
The cost of medicines for treating children and adults with
mild/moderate cholera at health centre (CMCM) is the
product of daily dosage of ORS; number of days that ORS
is administered; unit cost of ORS; and the number of chil-
dren and adults with mild/moderate cholera.
The cost of medicines for treating children aged under-1-
year-old, 1–4 years and 5–14 years, and adults (i.e. 15
years and above) with severe cholera at a hospital is the
product of dosage of erythromycin (and Ringer Lactate);
number of times a dosage of erythromycin is taken per
day; number of times a dosage of erythromycin is taken
per day; price per unit of erythromycin; and the number
of patients in relevant age bracket with severe cholera.
Simply, cost of medicines equals quantity consumed
times the unit price.
"Hotel" cost of component of health centre consultations 
and hospitalizations
The hospital cost per hospital stay and per outpatient visit
represent the "hotel" component (HC), i.e. excluding
drugs and diagnostic tests and including other costs such
as personnel, capital and food costs. The "hotel" compo-BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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nent of hospital costs were obtained from a WHO website
[9].
Hotel cost equals total cost of mild/moderate cholera
cases' outpatient department (OPD) consultations per
year plus total cost of severe cholera patients' hospitaliza-
tions per year. The first component is obtained by multi-
plying total number of mild/moderate cases; number of
OPD visits per mild/moderate patient per episode; and
cost per mild/moderate OPD consultation. The second
component is the product of total number of severe chol-
era patients hospitalized; average length of stay; and cost
per inpatient/day.
Cost of cholera diagnosis
Cost of cholera test equals total number of cholera cases
times cost of one cholera test. Thus, we assumed that all
the patients presenting at health centres and hospitals
manifesting cholera symptoms would undergo laboratory
diagnostic test to ascertain the cause.
Costs borne by households
The World Health Survey provided the general average
health care costs (consultation, medicines, tests and trans-
port) borne by households in 16 African countries, i.e.
Burkina Faso, Cote D'Ivoire, Congo, Comoros, Ethiopia,
Ghana, Kenya, Malawi, Mauritania, Mauritius, Namibia,
Senegal, Swaziland, South Africa, Zambia and Zimbabwe
[13]. The average health care cost per person was multi-
plied by total number of cases notified in each year to
obtain the total health care cost borne by households.
Indirect cost
The total indirect costs (IC) is the sum of total cost of pro-
ductive time lost due to mild/moderate cholera; total cost
of productive time lost due to severe cholera; total cost of
productive time lost due to cholera-related premature
mortality; and productivity loss due to the work time lost
by relatives accompanying and visiting patients.
Cost of premature cholera-related mortality
A total of 2230, 5281 and 2287 people died from cholera
in 2005, 2006 and 2007 respectively [8]. The distribution
of those deaths across the five age brackets was obtained
by multiplying the total number of cholera deaths by the
cholera-related probabilities of death (PD) from Murray
and Lopez [20]. Those authors estimated that the average
duration of each episode would last 0.02 years for all age
brackets. Thus, the productive life years lost (PLYL) for
each age bracket were obtained subtracting the sum of the
average age of onset and average duration of the episode
from the minimum, average and maximum life expectan-
cies in the African Region, respectively.
Total cost of premature cholera-related mortality is sum of
the cost of premature cholera-related mortality among
persons aged 4 years and less, aged 5–14 years, aged 15–
44 years, aged 45–59 years, and aged 60 years and above.
The cost of premature cholera-related mortality among
persons of specific age group is the product of number of
deaths, total number of productive discounted life years
lost (i.e. years above 14 years of age) and gross national
income per capita per year (US$). The productive life
years lost were discounted at a rate of 3% [17].
Cost of productive time lost due to severe cholera
Total cost of productive time lost due to temporary disa-
bility from severe cholera episodes (CPTSC) is the sum of
cost of productive time lost due to severe cholera among
persons aged 5–14 years, 15–44 years, 45–59 years, and
60 years and over. The non-fatal illness time lost among
patients aged 4 years and less was not costed.
The cost of productive time lost due to severe cholera
among persons of various age groups was obtained by
multiplying the total number of severe cholera cases, aver-
age duration lived with cholera and gross national income
per capita per year.
Cost of productive time lost due to mild/moderate cholera
Total productive time lost due to mild/moderate cholera
episodes (CPTMC) is the sum of cost of productive time
lost due to mild/moderate cholera among persons aged
5–14 years, 15–44 years, 45–59 years, and 60 years and
over. The non-fatal illness time lost among patients aged
4 years and less was not costed.
The cost of productive time lost due to mild/moderate
cholera episodes among persons of various age groups
was obtained by multiplying the total number of mild/
moderate cholera cases, average number of days lived
with mild/moderate cholera and daily gross national
income per capita.
Cost of productive time lost by care-givers accompanying 
patients for treatment
The cost of the work time lost by accompanying/visiting
relatives is a product of the number of cholera cases,
number of persons travelling to a health facility (i.e. the
accompanying relative), number of days spent visiting a
health facility per person per year and daily gross national
income per capita per day.
The assumptions used in estimating direct and indirect
costs can be found in the Appendix [see Additional file 1].
All the costs for 2005, 2006 and 2007 were expressed in
2002 prices using appropriate consumer price indices
from the International Monetary Fund database [14].B
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Table 2: Direct and indirect real cost of cholera (US$) in 2005 (at 2002 prices)
Scenario 1: At maximum life expectancy 
of 73 years
Scenario 2: At average life expectancy of 
53 years
Scenario 3: At minimum life expectancy 
of 40 years
Summary of direct costs of cholera US$ % of grand TC US$ % of grand TC US$ % of grand TC
(A). Direct costs
(1) Annual cost of medicines used in treating 
children and adults suffering mild/moderate cholera 
state at health centre
185,334 0.29 185,334 0.35 185,334 0.48
(2) Annual cost of medicines used in treating 
children and adults suffering severe cholera state at 
hospitals
71,561 0.11 71,561 0.13 71,561 0.18
(3) "Hotel" cost component of mild/moderate 
cholera cases consultations at health centres
2,740,314 4.27 2,740,314 5.15 2,740,314 7.03
(4) "Hotel" cost component of severe cholera cases 
hospitalization
651,741 1.02 651,741 1.22 651,741 1.67
(5) Cost cholera-related tests all cholera cases 1,615,047 2.52 1,615,047 3.03 1,615,047 4.15
(6) Health care cost borne by households 273,201 0.43 273,201 0.51 273,201 0.70
Total Direct Costs 5,537,198 8.62 5,537,198 10.40 5,537,198 14.21
(B) Indirect costs
(7) Cost of disablement among severe cases 63,879 0.10 63,879 0.12 63,879 0.16
(8) Cost of disablement among mild/moderate 
cases
531,242 0.83 531,242 1.00 531,242 1.36
(9) Cost of premature deaths 56,691,858 88.29 45,723,836 85.88 31,441,728 80.71
(10) Productivity loss for care-givers 1,384,702 2.16 1,384,702 2.60 1,384,702 3.55
Total Indirect Costs 58,671,681 91.38 47,703,659 89.60 33,421,551 85.79
Grand total cost 64,208,880 100 53,240,859 100 38,958,750 100BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
Page 7 of 14
(page number not for citation purposes)
Results
Total costs
Table 2 presents three scenario estimates of the direct and
indirect costs of cholera in the WHO African Region in
2005. This study estimated the real total economic loss
attributable to cholera to have been US$38,958,750
assuming a minimum regional life expectancy of 40 years;
US$53,240,859 assuming a regional average life expect-
ancy of 53 years; and US$64,208,880 assuming a maxi-
mum regional life expectancy of 73 years. The latter
estimate consisted of a total direct cost of US$5,537,200
(8.51%). Out of that direct cost, 3.35% consisted of cost
of medicines used in treating children and adults suffering
mild/moderate cholera state at health centre; 1.29% con-
sisted of cost of medicines used in treating children and
adults suffering severe cholera state at hospitals; 49.49%
consisted of the "hotel" cost component of mild/moder-
ate cholera cases consultations at health centres; 11.77%
consisted of the "hotel" cost component of severe cholera
cases hospitalization; 29.17% for cholera-related diagnos-
tic test; and 4.93% for health care costs incurred by house-
holds (patients and their family members) in search of
cholera treatment.
The indirect costs amounted to US$58,671,681 (91.39%
of total loss) worth of productive time that was lost by
people of the African Region due to cholera disease. Out
of the total indirect cost, about 96.63% was attributed to
premature cholera-related mortality; 0.11% to productive
time lost among severe cases; 0.91% to productive time
lost among mild/moderate cholera cases; and 2.36% to
productive time lost by family care givers.
Table 3 portrays three scenario estimates of the direct and
indirect costs of cholera in the WHO African Region in
2006. This study estimated the real total economic loss
attributable to cholera to have been US$ 91,863,606
assuming a minimum regional life expectancy of 40 years;
US$ 128,136,952 assuming a regional average life expect-
ancy of 53 years; and US$ 155,993,261 assuming a maxi-
mum regional life expectancy of 73 years. The latter
estimate was made up of US$8.6 million (5.5%) of direct
cost and US$147.4 million (94.5%) of indirect cost.
Table 4 depicts three scenario estimates of the direct and
indirect costs of cholera in the WHO African Region in
2007. This study estimated the real total economic loss
attributable to cholera to have been US$ 43,313,121
assuming a minimum regional life expectancy of 40 years;
US$ 59,913,137 assuming a regional average life expect-
ancy of 53 years; and US$ 72,661,207 assuming a maxi-
mum regional life expectancy of 73 years. The last
estimate was made up of US$4.8 million (6.58%) of
direct cost and US$67.9 million (93.42%) of indirect cost.
The use of three life expectancies affects only the magni-
tudes of the productive time lost due to premature death.
It can be seen in Tables 2, 3 and 4 that the cost of prema-
ture mortality varies directly with life expectancy.
Average costs
Tables 5, 6 and 7 presents an average real cost per mild/
moderate case of cholera, and average cost per severe case
of cholera, and average cost per cholera death (US$) in
years 2005, 2006 and 2007 respectively. The averages in
the three tables were obtained by dividing the itemized
total costs in Tables 2, 3 and 4 by the respective year's
number of mild/moderate cases, severe cases, and chol-
era-related deaths.
Cost of medicines for mild/moderate cholera case was
US$1.4–$1.6; cost of medicines for severe cholera case
was US$6.0–$7.0; cost of health centre consultation per
mild/moderate cholera case was US$20.9–$24.4; cost of
hospital admission per severe cholera case was $56.2–
$63.7; cost per cholera test was US$12.7–$15.5; health
care cost borne by cholera patient was US$2.1–$2.5; cost
of productive time lost per severe cholera case was
US$6.2–$7.1; cost of productive time lost per mild/mod-
erate cholera case was US$4.7–US$5.4; and cost of pro-
ductive time lost during travel per care giver was
US$11.1–$12.6. Cost of productive time lost per prema-
ture death was US$14,099.4–US$25,422.4 in 2005;
US$15,121.2–US$27,264.6 in 2006; and US$15,979.2–
US$28,811.8 in 2007.
Tables 8, 9 and 10 provides the average real cost per per-
son with cholera (US$) in 2005, 2006 and 2007 respec-
tively. These averages were obtained by dividing the
itemized total costs in Tables 2, 3 and 4 by 125018,
203564 and 110,837 cholera cases in year 2005, 2006 and
2007 respectively. During the three years the average cost
of medicines per person with cholera ranged between
US$1.8–US$2.1; US$23.4–US$27.1 for provider consul-
tation; US$12.7–US$15.5 for cholera test; US$2.1–
US$2.5 for health care cost borne by family; and
US$15.8–US$23.7 for productive time lost by patients
and family care givers. The average cost of productive time
lost due to premature mortality per person with cholera
was US$453.5–US$707.3 assuming a maximum regional
life expectancy of 73 years; US$365.7–US$570.5 assum-
ing a regional average expectancy of 53 years; and
US$251.5–US$392.3 assuming a regional minimum life
expectancy of 40 years.
In 2005 the average grand total cost per person with chol-
era was US$312, US$426 and US$514 assuming a life
expectancy of 40, 53 and 73 years respectively. The aver-
age grand total cost per person with cholera increased in
2006 to US$451, US$629 and US$766 at 40, 53 and 73
years respectively. In 2007, due to a decrease in notifiedB
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Table 3: Direct and indirect real cost of cholera (US$) in 2006 (at 2002 prices)
Scenario 1: At maximum life expectancy of 
73 years
Scenario 2: At average life expectancy of 
53 years
Scenario 3: At minimum life expectancy of 
40 years
Summary of direct costs of cholera US$ % of grand TC US$ % of grand TC US$ % of grand TC
(A). Direct costs
(1) Annual cost of medicines used in treating 
children and adults suffering mild/moderate 
cholera state at health centre
277,058 0.18 277,058 0.22 277,058 0.30
(2) Annual cost of medicines used in treating 
children and adults suffering severe cholera 
state at hospitals
107,950 0.07 107,950 0.08 107,950 0.12
(3) "Hotel" cost component of mild/moderate 
cholera cases consultations at health centres
4,096,527 2.63 4,096,527 3.20 4,096,527 4.46
(4) "Hotel" cost component of severe cholera 
cases hospitalization
1,062,965 0.68 1,062,965 0.83 1,062,965 1.16
(5) Cost cholera-related tests all cholera cases 2,580,675 1.65 2,580,675 2.01 2,580,675 2.81
(6) Health care cost borne by households 434,551 0.28 434,551 0.34 434,551 0.47
Total Direct Costs 8,559,726 5.49 8,559,726 6.68 8,559,726 9.32
(B) Indirect costs
(7) Cost of disablement among severe cases 111,551 0.07 111,551 0.09 111,551 0.12
(8) Cost of disablement among mild/moderate 
cases
919,340 0.59 919,340 0.72 919,340 1.00
(9) Cost of premature deaths 143,984,575 92.30 116,128,266 90.63 79,854,920 86.93
(10) Productivity loss for care-givers 2,418,069 1.55 2,418,069 1.89 2,418,069 2.63
Total Indirect Costs 147,433,535 94.51 119,577,226 93.32 83,303,880 90.68
Grand total cost 155,993,261 100 128,136,952 100 91,863,606 100B
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Table 4: Direct and indirect real cost of cholera (US$) in 2007 (at 2002 prices)
Summary of direct costs of cholera Scenario 1: At maximum life expectancy 
of 73 years
Scenario 2: At average life expectancy of 
53 years
Scenario 3: At minimum life expectancy 
of 40 years
US$ % of grand TC US$ % of grand TC US$ % of grand TC
(A). Direct costs
(1) Annual cost of medicines used in treating 
children and adults suffering mild/moderate 
cholera state at health centre
140,729 0.19 140,729 0.23 140,729 0.32
(2) Annual cost of medicines used in treating 
children and adults suffering severe cholera state 
at hospitals
54,508 0.07 54,508 0.09 54,508 0.13
(3) "Hotel" cost component of mild/moderate 
cholera cases consultations at health centres
2,080,794 2.84 2,080,794 3.47 2,080,794 4.80
(4) "Hotel" cost component of severe cholera 
cases hospitalization
510,332 0.70 510,332 0.85 510,332 1.18
(5) Cost cholera-related tests all cholera cases 1,722,805 2.35 1,722,805 2.88 1,722,805 3.98
(6) Health care cost borne by households 271,798 0.37 271,798 0.45 271,798 0.63
Total Direct Costs 4,780,966 6.58 4,780,966 7.98 4,780,966 11.04
(B) Indirect costs
(7) Cost of disablement among severe cases 64,184 0.27 64,184 0.11 64,184 0.15
(8) Cost of disablement among mild/moderate 
cases
532,118 2.27 532,118 0.89 532,118 1.23
(9) Cost of premature deaths 65,892,630 89.90 53,144,560 88.70 36,544,544 84.37
(10) Productivity loss for care-givers 1,391,308 1.03 1,391,308 2.32 1,391,308 3.21
Total Indirect Costs 67,880,240 93.42 55,132,170 92.02 38,532,154 88.96
Grand total cost 72,661,207 100 59,913,137 100 43,313,121 100BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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cholera cases, the average grand total cost decreased to
US$391, US$541 and US$656 at 40, 53 and 73 years
respectively.
Discussion
Key findings
The 125018 cases of cholera notified to WHO by coun-
tries of the African Region in 2005 resulted in a total eco-
nomic loss of US$39 million, US$ 53.2 million and
US$64.2 million assuming a regional life expectancies of
41, 53 and 73 years, respectively. The 203,564 cases of
cholera notified in 2006 led to a total economic loss
US$91.9 million, US$128.1 million and US$156 million
assuming life expectancies of 40, 53 and 73 years respec-
tively. The 110,837 cases of cholera notified in 2007
resulted in an economic loss of US$43.3 million, US$60
Table 5: Average cost per mild/moderate and severe case of cholera and cholera death (US$) in 2005 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Cost per case (US$) Cost per case (US$) Cost per case (US$)
(1) Cost of medicines per mild/
moderate cholera case
1.6 1.6 1.6
(2) Cost of medicines per severe 
cholera case
7.0 7.0 7.0
(3) Cost of health centre 
consultation per mild/moderate 
cholera case
24.4 24.4 24.4
(4) Cost per hospital admission of 
per severe cholera case
63.6 63.6 63.6
(5) Cost per cholera test 12.9 12.9 12.9
(6). Health care cost borne by 
cholera patient
2.2 2.2 2.2
(7). Cost of productive time lost 
per severe cholera case
6.2 6.2 6.2
(8). Cost of productive time lost 
per mild/moderate cholera case
4.7 4.7 4.7
(9). Cost of productive time lost 
per premature death
25422.4 20504.0 14099.4
(10). Cost of productive time lost 
in travel per care giver
11.1 11.1 11.1
Table 6: Average cost per mild/moderate and severe case of cholera and cholera death (US$) in 2006 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Cost per case (US$) Cost per case (US$) Cost per case (US$)
(1) Cost of medicines per mild/
moderate cholera case
1.5 1.5 1.5
(2) Cost of medicines per severe 
cholera case
6.5 6.5 6.5
(3) Cost of health centre 
consultation per mild/moderate 
cholera case
22.6 22.6 22.6
(4) Cost of hospital admission per 
severe cholera case
63.7 63.7 63.7
(5) Cost per cholera test 12.7 12.7 12.7
(6). Health care cost borne by 
cholera patient
2.1 2.1 2.1
(7). Cost of productive time lost 
per severe cholera case
6.7 6.7 6.7
(8). Cost of productive time lost 
per mild/moderate cholera case
5.1 5.1 5.1
(9). Cost of productive time lost 
per premature death
27264.6 21989.8 15121.2
(10). Cost of productive time lost 
in travel per care giver
11.9 11.9 11.9BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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million and US$77.7 million assuming life expectancies
of 40, 53 and 73 years respectively. The main driver of
costs of cholera in this study is the premature deaths of
young children.
The accuracy these estimates hinges on the plausibility of
the assumptions contained in the Appendix [see Addi-
tional file 1]; and their interpretation should be tempered
with the limitations highlighted below. The reader should
keep in mind that the purpose of total cost of illness stud-
ies such as the one reported in this paper is not to guide
policy decisions but instead to raise awareness among
policy-makers and the public about the negative eco-
nomic impact of cholera. In addition, it is worth noting
that many other diarrhoeal, respiratory, and vector borne
diseases exacts a greater toll of child mortality than that of
cholera.
Limitations of the study
a) Use of the standard treatment guidelines
We have assumed that WHO treatment guidelines for
cholera reflect actual practice. In reality this might not be
the case. Unfortunately, we did not have information on
what fraction of cases actually received the standard treat-
Table 7: Average cost per mild/moderate and severe case of cholera and cholera death (US$) in 2007 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Cost per case (US$) Cost per case (US$) Cost per case (US$)
(1) Cost of medicines per mild/
moderate cholera case
1.4 1.4 1.4
(2) Cost of medicines per severe 
cholera case
6.0 6.0 6.0
(3) Cost of health centre 
consultation per mild/moderate 
cholera case
20.9 20.9 20.9
(4) Cost of hospital admission per 
severe cholera case
56.2 56.2 56.2
(5) Cost per cholera test 15.5 15.5 15.5
(6). Health care cost borne by 
cholera patient
2.5 2.5 2.5
(7). Cost of productive time lost 
per severe cholera case
7.1 7.1 7.1
(8). Cost of productive time lost 
per mild/moderate cholera case
5.4 5.4 5.4
(9). Cost of productive time lost 
per premature death
28811.8 23237.7 15979.2
(10). Cost of productive time lost 
in travel per care giver
12.6 12.6 12.6
Table 8: Average cost per person with cholera (US$) in 2005 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Average cost per person with
cholera US$)
Average cost per person with
cholera (US$)
Average cost per person with
cholera (US$)
(1) Cost of medicines 2.1 2.1 2.1
(2) Cost of consultation/
hospitalization
27.1 27.1 27.1
(3) Cost of cholera test 12.9 12.9 12.9
(4). Health care cost borne by 
cholera patient
2.2 2.2 2.2
(5). Cost of productive time lost 15.8 15.8 15.8
(6). Cost of productive time lost 
due to premature death
453.5 365.7 251.5
(7). Total cost per person with 
cholera
513.6 425.9 311.6BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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ment and what proportion did not. In addition, we were
not in a position to speculate the implications of non-
adherence on the total cost of cholera illness.
b) Assumption that those who suffer cholera mortality would have 
future earning
In this study we assumed that all those who die from chol-
era would have future earnings. This assumption can be
contested especially in African countries where the formal
sectors are small and hence the proportion of people in
formal employment is small. In situations where unem-
ployment rate is high, the marginal productivity of labor
might be less than the average. Should this be the case, the
use of gross national income per capita might over-esti-
mate the economic burden of cholera.
c) Assumption that all cholera cases receive a diagnostic test
We have assumed that all cholera cases receive a diagnos-
tic test. In reality, this might not be the case. We used an
average cost obtained from a number of countries in the
African Region. By so doing we may have overestimated
the cost of diagnosis.
d) Omission of intangible costs
The majority of the data used in this study were obtained
from secondary sources due to research resource con-
straints. Therefore, it was not possible to conduct a house-
hold survey that would have made it possible to estimate
the intangible costs using contingent willingness-to-pay
approach [21].
e) Use of per capita GNI to value-productive time lost
This study attempted to estimate the loss in the gross
national income (GNI) and not the total economic cost of
cholera morbidity and premature mortality. The social
value of the contribution that women make to African
societies is greater than that captured in GNI calculations.
This is because the International Labour Organization's
Table 9: Average cost per person with cholera (US$) in 2006 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Average cost per person with
cholera US$)
Average cost per person with
cholera (US$)
Average cost per person with
cholera (US$)
(1) Cost of medicines 1.9 1.9 1.9
(2) Cost of consultation 25.3 25.3 25.3
(3) Cost of cholera test 12.7 12.7 12.7
(4). Health care cost borne by 
cholera patient
2.1 2.1 2.1
(5). Cost of productive time lost 16.9 16.9 16.9
(6). Cost of productive time lost 
due to premature death
707.3 570.5 392.3
(7). Total cost per person with 
cholera
766.3 629.5 451.3
Table 10: Average cost per person with cholera (US$) in 2007 (at 2002 prices)
Scenario 1: Maximum life
expectancy of 73 years
Scenario 2: Average life
expectancy of 53 years
Scenario 3: Minimum life
expectancy of 40 years
Types of costs per person Average cost per person with
cholera US$)
Average cost per person with
cholera (US$)
Average cost per person with
cholera (US$)
(1) Cost of medicines 1.8 1.8 1.8
(2) Cost of consultation 23.4 23.4 23.4
(3) Cost of cholera test 15.5 15.5 15.5
(4). Health care cost borne by 
cholera patient
2.5 2.5 2.5
(5). Cost of productive time lost 23.7 23.7 23.7
(6). Cost of productive time lost 
due to premature death
594.5 479.5 329.7
(7). Total cost per person with 
cholera
655.6 540.6 390.8BMC International Health and Human Rights 2009, 9:8 http://www.biomedcentral.com/1472-698X/9/8
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(ILO) definition of labour force includes the employed
(including the armed forces), the unemployed, and the
first-time job-seekers, but excludes full-time homemakers
and other unpaid caregivers and workers in the informal
sector. The majority of the women in Africa are either full-
time homemakers and/or informal sector workers, and,
thus, their invaluable contribution to society is excluded
from GNI calculations [22,23].
f) Omission of economic effects of cholera outbreaks on tourism and 
commodity export
We mentioned in the Methods section that when there are
cholera outbreaks in African countries, developed coun-
tries usually discourage their citizens from traveling to the
affected countries, which reduces the number of tourists
to those countries. Consequently, that leads to losses of
revenues for the tourism industry, unemployment of peo-
ple whose livelihood is dependent on tourism, and reduc-
tion in tax revenues for the governments. In addition,
usually, there is an international embargo on export of
commodities from countries experiencing cholera out-
breaks. When the latter happens, it may adversely affect
the foreign exchange flow into the affected countries,
which is likely to have many other externality costs.
Conclusion
In spite of data limitations, the estimates reported here
show that cholera imposes substantial economic burden
on countries of the African Region. That heavy burden
underscores the urgent need for increased investments in
the prevention and control of cholera.
In addition, there is an urgent need for further research to
determine:
￿ national-level economic burden of cholera, broken
down by different productive and social sectors and
occupations of patients and relatives; and
￿ national-level costs, effectiveness and monetary ben-
efits of alternative ways of scaling up population cov-
erage of appropriate potable water and clean
sanitation facilities in rural, peri-urban and urban
areas.
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